23andMe is operating through Chapter 11 process, plans to sell assets, prioritizing customer privacy.

From GlobeNewswire: 2025-03-26 18:57:00

Genetics and biotechnology company 23andMe has received approval from the U.S. Bankruptcy Court for its Chapter 11 petitions. The company will continue to operate during the Chapter 11 process, prioritizing customer privacy. 23andMe plans to sell its assets and has initiated a 45-day bidding process. A second hearing is scheduled for April 22 to further support operations. Advisors and legal counsel have been appointed, and the company remains committed to empowering a healthier future through genetics-led consumer healthcare. For more information, visit www.23andme.com.



Read more at GlobeNewswire: 23andMe Confirms All Potential Buyers Must Agree to Comply